Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
Ibandronate was granted FDA approval on 16 May 2003.
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 545
- Registration Number
- NCT02598453
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT02598440
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02564107
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT02561039
A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT02553707
Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
- Conditions
- Osteoporosis
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Clinic of Endocrinology and Metabolic Disorders, Macedonia
- Target Recruit Count
- 700
- Registration Number
- NCT02271204
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis
- Conditions
- Aseptic Hip NecrosisHip Necrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Brigitte Jolles, MD
- Target Recruit Count
- 8
- Registration Number
- NCT02114489
- Locations
- 🇨🇭
Lausanne University Hospital, Lausanne, Vaud, Switzerland
Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 100
- Registration Number
- NCT01627886
- Locations
- 🇮🇳
BA Research India Ltd, Ahmedabad, Gujarat, India
Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 105
- Registration Number
- NCT01429675
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 659
- Registration Number
- NCT01381393
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.